Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ISRCTN18346744) titled 'A study to evaluate the safety of NTX-1955 in patients with generalised anxiety disorder' on March 6.
Study Type: Interventional
Study Design:
Double-blind randomized placebo-controlled parallel-group trial (Safety)
Primary Sponsor: Newleos Therapeutics
Condition:
Generalized anxiety disorder (GAD)
Mental and Behavioural Disorders
Intervention:
Participants will be randomised using an Interactive Response Technology (IRT) system to one of the three following treatment arms:
1. 25 mg NTX-1955
2. 15 mg NTX-1955
3. Placebo
Participants in each treatment arm will be required to take one capsule of either 25 m...